A phase II, eight week, multi-center, open label trial of Xyrem (sodium oxybate) for excessive daytime sleepiness and nocturnal sleep disturbance in patients with mild to moderate Parkinson's disease.
Phase of Trial: Phase II
Latest Information Update: 06 May 2009
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Parkinson's disease; Sleep disorders
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2008 New trial record.